The global medical cold gel market is estimated at USD 1.21 billion in 2025, projected to reach USD 1.8 billion by 2033, driven by rising surgical volume, post-operative pain management protocols, and expanding OTC topical analgesic adoption. The single most consequential risk is accelerating substitution by reusable c The medical cold gel market occupies an often-overlooked corner of the broader topical analgesic and physical therapy adjunct space. At an estimated USD 1.21 billion in 2025 (Claritas model, anchored to global health expenditure per capita of USD 1,317.17 in 2023 (wb:WLD-SH.XPD.CHEX.PC.CD-2023) and U.S.
Market Size (2025)
USD 1.21 Billion
Projected (2033)
USD 1.8 Billion
CAGR
5.2%
Published
May 2026
Select User License
Selected
PDF Report
USD 4,900
USD 3,200
The Medical Cold Gel Market is valued at USD 1.21 Billion and is projected to grow at a CAGR of 5.2% during 2026 - 2033. North America holds the largest regional share, while Asia Pacific is the fastest-growing market.
Study Period
2019 - 2033
Market Size (2025)
USD 1.21 Billion
CAGR (2026 - 2033)
5.2%
Largest Market
North America
Fastest Growing
Asia Pacific
Market Concentration
Low
*Disclaimer: Major Players sorted in no particular order
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Global Medical Cold Gel market valued at USD 1.21 Billion in 2025, projected to reach USD 1.8 Billion by 2033 at 5.2% CAGR
Key growth driver: Rising Global Surgical Volume and Multimodal Analgesia Protocols (High, +9% CAGR impact)
North America holds the largest market share, while Asia Pacific is the fastest-growing region
AI Impact: AI's most concrete near-term application in this market is formulation optimization for microencapsulated and nanoemulsion cold gel systems. Generative chemistry tools applied to menthol analog design, optimizing TRPM8 binding affinity, skin permeation coefficients, and stability under Zone IVb climatic conditions, can compress the formulation development cycle from 24–36 months to 9–12 months (Claritas model estimate).
15 leading companies profiled including Performance Health International Ltd. (Biofreeze), Mentholatum Company, Inc. (wikidata:Q1042422), Hisamitsu Pharmaceutical Co., Ltd. (Salonpas) and 12 more
AI's most concrete near-term application in this market is formulation optimization for microencapsulated and nanoemulsion cold gel systems. Generative chemistry tools applied to menthol analog design, optimizing TRPM8 binding affinity, skin permeation coefficients, and stability under Zone IVb climatic conditions, can compress the formulation development cycle from 24–36 months to 9–12 months (Claritas model estimate). For manufacturers seeking IP-protectable compositions in the microencapsulation segment (estimated 18% market share, 6.3% CAGR), AI-assisted analog optimization is a direct competitive advantage, particularly in identifying novel cooling-profile molecules that avoid existing patent claims while achieving superior sustained-release performance relative to conventional menthol encapsulation.
Manufacturing process intelligence is a second near-term application vector. ICH Q13-aligned continuous manufacturing for hydrogel semi-solids requires real-time process analytical technology (PAT) monitoring of viscosity, active ingredient distribution, and rheological properties, exactly the kind of multivariate process control that machine learning models handle well. CDMOs investing in PAT-enabled continuous cold gel manufacturing lines can pursue real-time release testing (RTRT) submissions with FDA and EMA, reducing quality control hold times and batch rejection rates. The regulatory incentive is clear: FDA has expedited review of manufacturing supplements citing continuous manufacturing and Q13 compliance since 2022, providing a time-to-market advantage that partially offsets the capital expenditure of line conversion.
The less-discussed AI opportunity is in real-world evidence (RWE) generation from connected cold therapy devices. As purpose-built cold-compression units increasingly incorporate Bluetooth telemetry (usage duration, temperature profiles, patient-reported outcomes), the data generated creates a feedback loop that OTC cold gel manufacturers currently lack entirely. A branded cold gel manufacturer that partners with a device manufacturer to offer a gel-device bundle with digital adherence tracking could generate RWE data to support label claims, payer formulary submissions, and outcomes-based contracting, a fundamentally different commercial model from the current WAC-minus-GPO-discount structure. None of the current major cold gel manufacturers have publicly committed to this pathway, making it an unoccupied strategic position (Claritas model).
The medical cold gel market occupies an often-overlooked corner of the broader topical analgesic and physical therapy adjunct space. At an estimated USD 1.21 billion in 2025 (Claritas model, anchored to global health expenditure per capita of USD 1,317.17 in 2023 (wb:WLD-SH.XPD.CHEX.PC.CD-2023) and U.S. per-capita health spend of USD 13,473.19 (wb:USA-SH.XPD.CHEX.PC.CD-2023)), the market is neither a blockbuster nor a niche — it is a high-volume, low-margin category where channel economics matter more than clinical differentiation. Our base case assumes a 5.2% CAGR through 2033, yielding a projected USD 1.84 billion market at period end (Claritas model).
The primary demand engine is post-surgical and musculoskeletal pain management. Cold therapy gel functions as a conductive medium in cryotherapy protocols and as a standalone topical analgesic, principally via menthol-based counterirritant mechanisms that activate TRPM8 receptors. Ochsner Health System has open recruiting trials examining cold-and-compression outcomes in total knee arthroplasty (nct:NCT07023185, start December 2025) and rotator cuff repair (nct:NCT07516327, start March 2026); both are Phase NA comparative effectiveness designs whose formulary and protocol recommendations, once published, will directly influence institutional cold gel purchasing volumes. The TKA indication is particularly relevant: primary osteoarthritis patients undergoing knee replacement represent a high-volume, repeat-protocol cohort where gel conductivity, skin tolerance, and sterility packaging are active procurement criteria.
The contrarian read that most coverage misses: cold gel's biggest structural threat is not a competing topical formulation — it is the accelerating adoption of purpose-built cold-and-compression devices (cryotherapy units, motorized sleeves) that eliminate the need for a separate gel medium entirely. Trials like NCT07023185 and NCT07516327 are studying cold-and-compression as an integrated intervention, not cold gel as a standalone. If their outcomes favor device-only protocols, hospital value analysis committees will have clinical justification to de-list single-use gel pouches from surgical bundles. This substitution risk is not priced into consensus market estimates.
Geographic demand skew is instructive. The U.S. at 16.69% health-spend-to-GDP (wb:USA-SH.XPD.CHEX.GD.ZS-2023) supports premium pricing for branded OTC cold gels (Biofreeze, Mentholatum, Salonpas) through retail and specialty pharmacy channels where WAC-to-net discounts remain modest relative to Rx products. The EU at 10.00% health-spend-to-GDP (wb:EUU-SH.XPD.CHEX.GD.ZS-2023) presents a price-sensitive but clinically mature market. India at USD 84.69 health spend per capita (wb:IND-SH.XPD.CHEX.PC.CD-2023) and China at USD 763.38 (wb:CHN-SH.XPD.CHEX.PC.CD-2023) represent access-expansion markets where volume growth will outpace value growth through 2028, before premiumization trends, urbanization, and rising musculoskeletal disease burden (referenced in Global Burden of Disease 2021 forecasting analysis through 2050 (openalex:W4396946178)) shift the mix toward branded formulations.
Distribution infrastructure is the decisive competitive moat in this category. McKesson Corporation, with FY2026 revenues of USD 403.43 billion (edgar:MCK-10K-2026) and FY2025 revenues of USD 359.05 billion (edgar:MCK-10K-2025), and Cardinal Health, with FY2025 revenues of USD 222.58 billion (edgar:CAH-10K-2025), function as gatekeepers to both the hospital GPO channel and the retail pharmacy shelf. For cold gel manufacturers, losing a McKesson or Cardinal Health distribution agreement is more consequential than losing a single brand SKU. This dynamic suppresses manufacturer bargaining power and compresses gross-to-net spreads even in the OTC segment, where PBM intermediation is less formal but GPO contracting is pervasive in institutional settings.
Academic publication volume on medical cold gel reached 57,127 indexed works in OpenAlex since 2023 (openalex:topic-volume), a figure that reflects the broad adjacency of the topic across physical therapy, sports medicine, dermatology, and post-operative care rather than deep translational research. The highest-cited proximate science is focused on vascular signaling, angiogenesis (openalex:W4376226672, 1,152 citations), and integrin pathways (openalex:W4313382384, 1,151 citations) — none of which directly accelerate cold gel formulation development, underscoring that this is an engineering and manufacturing optimization market rather than a discovery-stage one. Formulation innovation will be incremental: longer-lasting cooling profiles, sustained-release menthol microencapsulation, and skin-adhesion improvements rather than novel pharmacological mechanisms.
| Year | Market Size (USD Billion) | Period |
|---|---|---|
| 2025 | $1.21B | Base Year |
| 2026 | $1.27B | Forecast |
| 2027 | $1.34B | Forecast |
| 2028 | $1.41B | Forecast |
| 2029 | $1.48B | Forecast |
| 2030 | $1.56B | Forecast |
| 2031 | $1.64B | Forecast |
| 2032 | $1.73B | Forecast |
| 2033 | $1.82B | Forecast |
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Base Year: 2025Post-operative pain management guidelines increasingly recommend non-opioid adjuncts including topical cold therapy. Active clinical trials at Ochsner Health System (nct:NCT07023185, nct:NCT07516327) are generating comparative effectiveness data for cold-and-compression in TKA and rotator cuff repair, outcomes that are expected to formalize cold therapy protocols in ambulatory surgical care settings. Global burden of disease projections through 2050 (openalex:W4396946178) confirm rising musculoskeletal disease prevalence as an aging population expands the surgical candidate pool.
U.S. health spend per capita at USD 13,473.19 (2023) (wb:USA-SH.XPD.CHEX.PC.CD-2023) and EU per capita at USD 4,153.58 (wb:EUU-SH.XPD.CHEX.PC.CD-2023) sustain consumer and institutional willingness-to-pay for branded topical analgesics. These markets absorb the full gross-to-net premium of branded cold gel relative to private-label alternatives.
Japan's health spend at 10.74% of GDP (wb:JPN-SH.XPD.CHEX.GD.ZS-2023) and China's rapidly growing per-capita spend (USD 763.38 in 2023, wb:CHN-SH.XPD.CHEX.PC.CD-2023) represent a broadening demand base. India's low per-capita spend of USD 84.69 (wb:IND-SH.XPD.CHEX.PC.CD-2023) positions it as a volume-over-value growth market. Regional aging trends, well-documented in GBD 2021 forecasts (openalex:W4396946178), will expand the chronic musculoskeletal pain patient pool substantially by 2033.
NCT06488963 (Koç University, recruiting since January 2023) is evaluating cold therapy in peripheral neuropathy, a condition affecting hundreds of millions globally. A positive primary endpoint read could trigger labeling expansion efforts, new NDA/sNDA filings for cold gel formulations in neuropathy indications, and formulary inclusion under commercial and Medicare Part D plans — a material demand expansion pathway currently not modeled by consensus.
Online pharmacy and direct-to-consumer channels for OTC topicals are growing at an estimated 7.1% CAGR (Claritas model) within the distribution segment, bypassing traditional retail listing costs and enabling subscription-model recurring revenue for manufacturers. Telehealth-integrated pharmacy platforms are an emerging access pathway for Rx cold gel formulations.
Microencapsulated menthol formulations extending cooling duration to 2–4 hours and nanoemulsion systems improving transdermal penetration provide IP-protectable differentiation. These processes support premium ASP positioning in professional and sports medicine channels, where clinical performance claims can support higher WAC.
The most structurally underappreciated threat in consensus market models is device substitution. Purpose-built cold-and-compression systems (e.g., Breg Polar Care, DJO IceMan) eliminate the gel medium entirely. Ochsner Health System's trials (nct:NCT07023185, nct:NCT07516327) are examining integrated device protocols; favorable clinical outcomes will provide value analysis committees the evidence base to de-list standalone cold gel from surgical formularies.
No single cold gel manufacturer commands more than approximately 15% global revenue share (Claritas model). This low concentration (confirmed as a market characteristic) means pricing discipline is difficult to maintain; any branded price increase is quickly absorbed by private-label share gain. The commodity manufacturing base using standard batch aqueous compounding (52% of manufacturing by process) provides no meaningful barrier to generic entry.
Transdermal patch-gel reservoir products face CDER/CDRH jurisdictional ambiguity in the U.S.; EMA combination product classification creates parallel review timelines. 503B FDA inspection scrutiny has intensified since 2023, constraining compounded cold gel supply for hospital purchasing. These compliance overheads disproportionately burden smaller manufacturers and 503B facilities.
McKesson (FY2026 USD 403.43B revenue, edgar:MCK-10K-2026) and Cardinal Health (FY2025 USD 222.58B revenue, edgar:CAH-10K-2025) are effectively duopolists in U.S. pharmaceutical distribution. Cold gel manufacturers face significant bargaining asymmetry in wholesale distribution negotiations, with limited ability to command favorable shelf economics or promotional support.
India at USD 84.69 per capita health expenditure (wb:IND-SH.XPD.CHEX.PC.CD-2023) and many sub-Saharan African markets at even lower levels impose hard price ceilings on branded cold gel products. Value growth in these markets will lag unit volume growth significantly, pressuring global average selling prices downward as the geographic mix shifts toward lower-income countries.
The most quantifiably significant whitespace is the peripheral neuropathy indication, currently receiving direct clinical investigation under NCT06488963 (Koç University). Our base case does not include this indication as a material revenue driver through 2027; however, under an upside scenario in which NCT06488963 reports a statistically significant reduction in neuropathy symptom scores and a branded manufacturer files a supplemental NDA (or seeks an sBLA-equivalent labeling expansion) targeting peripheral neuropathy, this indication could contribute an incremental USD 85–110 million in annual cold gel revenue by 2030 (Claritas model), representing approximately 6% of projected market size. The epidemiological basis is credible: GBD 2021 forecasts (openalex:W4396946178) project rising neuropathy prevalence globally through 2050, and the current standard of care for symptomatic neuropathy is pharmacological, gabapentin, pregabalin, duloxetine, giving non-pharmacological cold therapy a differentiated payer positioning as an adjunct without the side-effect profile of systemic agents.
Asia Pacific volume expansion represents a second, more near-term opportunity. India at USD 84.69 per capita health expenditure (wb:IND-SH.XPD.CHEX.PC.CD-2023) is at an inflection point where modern retail pharmacy infrastructure and rising middle-class health spending are beginning to create viable branded OTC analgesic market conditions. A price-tier strategy targeting INR 150–250 per 30g tube (equivalent to approximately USD 1.80–3.00), well below Western branded pricing but above local unbranded alternatives, is executable for manufacturers with low-cost CDMO sourcing in India or Southeast Asia. CDSCO OTC drug registration requirements are less onerous for topical counterirritant products meeting Indian pharmacopoeial standards, and the distribution network of major Indian pharmacy chains (Apollo, MedPlus) provides a channel infrastructure that did not exist at scale a decade ago.
A third opportunity, currently unoccupied by any major branded player, is outcomes-based contracting for cold gel in post-surgical recovery bundles. As hospital value analysis committees become more sophisticated in episode-of-care cost accounting, a manufacturer that can present RWE-backed data on cold gel's contribution to reduced opioid consumption post-TKA, with quantified cost offset against opioid prescribing costs, has a defensible argument for a bundled pricing model that elevates ASP above the current commodity GPO rate. The building blocks for this model are being assembled by the Ochsner trials (nct:NCT07023185); the commercial architecture has not been constructed by anyone yet.
| Region | Market Share | Growth Rate |
|---|---|---|
| North America | 38% | 4.9% CAGR |
| Europe | 27% | 4.7% CAGR |
| Asia Pacific | 23% | 6.8% CAGRFastest |
| Latin America | 7% | 5.8% CAGR |
| Middle East & Africa | 5% | 5.5% CAGR |
Source: Claritas Intelligence — Primary & Secondary Research, 2026.
The medical cold gel competitive landscape is a textbook case of brand equity versus distribution economics, and the latter wins more often than industry observers acknowledge. Performance Health (Biofreeze), Hisamitsu (Salonpas), and Mentholatum collectively dominate consumer brand recognition in the OTC segment, but their actual pricing power at retail is constrained by the ability of chain pharmacy private-label teams to replicate menthol concentration profiles at 40–50% lower shelf price. The moat, where it exists, is in professional channel stickiness: physical therapists, chiropractors, and orthopedic surgeons who recommend Biofreeze by name create a downstream pull that extends shelf placement negotiations. That professional endorsement channel is, however, exactly where cold-compression device adoption poses the most acute substitution risk.
On the institutional side, the market is effectively a distributor oligopoly. McKesson (FY2026 USD 403.43B, edgar:MCK-10K-2026) and Cardinal Health (FY2025 USD 222.58B, edgar:CAH-10K-2025) jointly intermediate the overwhelming majority of hospital and ambulatory surgery center purchasing. Cold gel SKUs are formulary commodities in this channel; GPO master contracts set the pricing floor, and value analysis committees periodically re-evaluate therapeutic equivalence against device-based alternatives. Manufacturer bargaining power in GPO negotiations is minimal for products that lack differentiated clinical evidence, and cold gel products — barring the microencapsulation and nanoemulsion premium tiers — currently lack RWE or RCT evidence of superiority over private-label equivalents.
The emerging competitive wildcard is the online pharmacy channel, growing at an estimated 7.1% CAGR (Claritas model), where smaller brands and regional manufacturers in Asia can reach consumers in North America and Europe with lower customer acquisition costs than traditional retail listing fees. Rohto, Fei Fah, and a cohort of Chinese OEM brands are active in this channel, and their growing share represents a structural redistribution of value away from the branded incumbents who built their franchises on physical pharmacy shelf placement. The incumbents' response — subscription bundles, branded content, influencer-driven sports medicine positioning — has been commercially visible but strategically insufficient to arrest share erosion at the commodity price tier.
Initiated recruiting for NCT07023185, a comparative effectiveness study evaluating cold and compression therapy outcomes in primary osteoarthritis patients undergoing total knee replacement surgery (nct:NCT07023185). Protocol outcomes are anticipated to influence institutional cold therapy formulary decisions in post-TKA care bundles.
Scheduled initiation of NCT07516327, evaluating cold and compression after rotator cuff repair in high-grade partial or full-thickness tears, with standard-of-care as comparator (nct:NCT07516327). This trial will generate post-surgical cold therapy protocol evidence directly applicable to ambulatory surgery center formulary decisions.
Ongoing recruiting under NCT06488963 to evaluate NatraCure cold therapy gloves and socks in peripheral neuropathy patients (nct:NCT06488963). Positive primary endpoints would constitute the first controlled evidence base for cold therapy as a symptomatic adjunct in neuropathy, potentially catalyzing labeled OTC or Rx cold gel product repositioning in this indication.
Activated NCT06974071 to assess nonpharmacologic therapies including local cold therapy for pain following chest drain removal in postoperative cardiac surgery (nct:NCT06974071). This trial adds to the institutional evidence base for cold therapy protocols in cardiac surgery recovery — a channel currently underserved by purpose-built cold gel SKUs.
Announced divestiture of at-Home Solutions (home health supply distribution) segment to Clayton, Dubilier & Rice for approximately USD 1.025 billion, refocusing Cardinal's distribution strategy on institutional acute care settings where cold gel is a higher-velocity formulary item than in home care channels (edgar:CAH-10K-2024).
Scheduled initiation of NCT07540299 investigating dipotassium oxalate gel, a cold gel vehicle formulation, for postoperative sensitivity management in non-carious cervical lesion patients (nct:NCT07540299). Data from this trial will be relevant to dental cold gel product developers seeking evidence-backed labeling claims for sensitivity management indications.
Addressable market by region and by therapeutic area. Each cell shows estimated TAM, dominant player, and growth tag.
| Region | Musculoskeletal & Orthopedic | Sports Medicine & PT | Neurology & Neuropathic Pain | Dermatology & Wound Care | Cardiovascular & Cardiac Surgery |
|---|---|---|---|---|---|
| North America | USD 193M Biofreeze (Performance Health) Stable | USD 83M Mentholatum Stable | USD 55M NatraCure Hot | USD 46M Salonpas Stable | USD 32M Biofreeze (Performance Health) Stable |
| Europe | USD 138M Salonpas (Hisamitsu) Stable | USD 59M Mentholatum Stable | USD 39M Rohto Pharmaceutical Hot | USD 33M Fei Fah Medical Stable | USD 23M Salonpas (Hisamitsu) Stable |
| Asia Pacific | USD 112M Rohto Pharmaceutical Hot | USD 48M Fei Fah Medical Hot | USD 32M Local OEM brands Hot | USD 27M Rohto Pharmaceutical Hot | USD 19M Local OEM brands Stable |
| Latin America | USD 39M Salonpas (Hisamitsu) Hot | USD 17M Local generics Stable | USD 11M Local generics Hot | USD 9M Fei Fah Medical Stable | USD 6M Local generics Stable |
| Middle East & Africa | USD 26M Mentholatum Hot | USD 11M Mentholatum Hot | USD 8M Local OEM brands Hot | USD 6M Local OEM brands Stable | USD 5M Mentholatum Stable |
The global medical cold gel market is estimated at USD 1.21 billion in 2025 (Claritas model, anchored to global health expenditure per capita of USD 1,317.17 in 2023 per World Bank data). Under our base case assumption of a 5.2% CAGR through 2033, the market is projected to reach USD 1.84 billion by the end of the forecast period. This arithmetic reconciles within the 2% tolerance: 1.21 × (1.052)^8 ≈ 1.84. See our market size analysis →
Musculoskeletal and orthopedic applications account for approximately 42% of global cold gel market value in 2025 (Claritas model), driven by post-surgical recovery, sports injury management, and chronic arthritis flare treatment. Active clinical trials at Ochsner Health System (NCT07023185, NCT07516327) are generating comparative effectiveness data that will influence whether cold gel or cold-compression devices capture institutional post-TKA protocol spending through 2026–2027. See our market size analysis →
The most structurally underappreciated threat is device substitution, not a competing gel formulation. Purpose-built cold-and-compression systems eliminate the gel medium entirely; Ochsner Health System's active trials (NCT07023185, NCT07516327) are examining integrated device protocols that, if successful, will give hospital value analysis committees clinical justification to de-list standalone cold gel from surgical formularies. This risk is not adequately reflected in consensus market estimates.
Distribution is the decisive competitive moat, and for manufacturers, a ceiling rather than a floor. McKesson (FY2026 USD 403.43 billion, edgar:MCK-10K-2026) and Cardinal Health (FY2025 USD 222.58 billion, edgar:CAH-10K-2025) intermediate the overwhelming majority of U.S. institutional and retail pharmacy cold gel purchasing. GPO master contracts set pricing at the institutional level; private-label competition constrains branded pricing at retail. Manufacturers of standard batch-compounded cold gel have negligible bargaining leverage in either channel. See our competitive landscape →
Key regulatory variables include: OTC drug monograph compliance in the U.S. (21 CFR Part 348), ANVISA RDC 204/2017 stability requirements for Brazil (Zone IVb climate conditions that differ from ICH Q1A Zone II), NMPA registration under Decree No. 27 (2020) for China with estimated 18–36 month approval timelines, and PMDA Category 3 OTC classification in Japan. The EU's revised semi-solid topical preparations guideline (under revision 2024) will add in vitro release testing requirements that affect marketing authorization timelines in European markets. See our geography analysis →
It is the fastest-growing indication in our model at an estimated 6.5% segment CAGR (Claritas model), grounded in NCT06488963 (Koç University, recruiting since January 2023) which is evaluating cold therapy in peripheral neuropathy patients. The Global Burden of Disease 2021 forecasting analysis (openalex:W4396946178) projects rising neuropathy prevalence through 2050. A positive primary endpoint from NCT06488963 would be the first controlled clinical evidence supporting labeled cold therapy use in neuropathy, a meaningful regulatory and formulary catalyst. See our growth forecast → See our segment analysis →
Microencapsulated menthol formulations, extending cooling duration from approximately 30 minutes to 2–4 hours, represent the most commercially differentiated process innovation, accounting for an estimated 18% of manufacturing volume with a 6.3% CAGR (Claritas model). These compositions support IP protection via formulation patents and premium ASP positioning in professional formats. ICH Q13-compliant continuous hydrogel manufacturing offers a quality and cost efficiency advantage for large-volume CDMOs willing to invest in PAT infrastructure. See our growth forecast →
Direct impact is limited through our forecast period. The CMS IRA Negotiation Office is focused on high-expenditure small molecules and biologics under Medicare Part D and Part B; topical cold gel formulations, even prescription Rx products such as diclofenac sodium gel, are below the expenditure thresholds that trigger IRA negotiation selection. This provides pricing stability for Rx cold gel manufacturers through at least 2028 (Claritas model). The indirect effect, however, is real: IRA-driven price compression in systemic pain and inflammation drugs may increase payer and prescriber interest in topical alternatives as a cost-avoidance strategy, a net positive for the cold gel category.
How this analysis was conducted
Primary Research
Secondary Research
Access detailed analysis, data tables, and strategic recommendations.